Phibro Q1 net sales $260.4M (+13% YoY), net income $7.0M vs loss; updates FY25 guidance

PHIBRO ANIMAL HEALTH CORP

2025-Q1 EPS reported $0.17 revenue$260,432,000

Net sales $260.4M (+13% YoY); net income $7.0M vs net loss $8.0M; diluted EPS $0.17 vs -$0.20.
Adjusted EBITDA $30.7M, +64% YoY; adjusted diluted EPS $0.35 vs $0.14 prior year.
Updated FY2025 guidance: net sales $1.05B-$1.10B; Adjusted EBITDA $124M-$132M (15% growth).
Discontinued atopic dermatitis project; expects ~$200M sales from Zoetis MFA portfolio in FY2025.
Gross margin improved 280 bps to 32.1%; interest expense up $3.1M due to refinancing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.